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Summary
Recently a point mutation (G1691A) in the coagulation factor V 
gene was shown to cause resistance for cleavage by activated protein C. 
The mutation is associated with an increased thrombotic risk and thus- 
far the most common genetic cause o f thrombophilia, Current tech­
niques to investigate the single base pair mutation at the DNA level use 
an assay based upon the polymerase chain reaction followed by restric­
tion enzyme digestion or Southern blotting and allele specific probing, 
The method we describe here consists o f a single PCR in which two 
specially designed allele specific primers and two consensus primers 
were used in one reaction to distinguish between homozygous normal, 
heterozygous and homozygous mutant individuals, Amplification 
products were analysed using Capillary Electrophoresis and on line UV 
monitoring.
The Allele Specific Amplification Protocol and subsequent CE ana­
lysis (ASAP-CE) is a convenient, fast, automated and highly repro­
ducible method that can be used in a routine laboratory setting.
Introduction
In the anticoagulant pathway the role of Activated Protein C (APC), 
a vitamin-K-dependent serine proteinase, is to selectively inactivate pro 
coagulant factors Va and V illa (1). Using a new APC-resistance assay, 
Dahlback et al. (2) recently showed that an autosomal dominant trait is 
associated with venous thrombosis. Bertina et al. (3), Voorberg et al.
(4) and Greengard et al. (5) showed that a guanine to adenine point mu­
tation at nucleotide 1691 of the gene coding for coagulation factor V 
(G1691A) is strongly associated with venous thrombosis. The mutation 
leads to substitution of the arginine residue at position 506 of the 
protein by glutamine. The presence of arginine 506 is essential for the 
proteolytic inactivation of factor V by APC and the conversion to gluta­
mine is therefore responsible for the resistance to APC cleavage. The 
factor V mutation is estimated to be present in 2-4%  of the Dutch 
population (3) and in 7% of the Swedish population (6). It was shown 
to be associated with a three-fold increase in thrombotic risk (3, 7). 
About 40-50% of patients with familial thrombophilia show APC 
resistance, this makes factor V G1691A mutation the most common 
genetic cause of thrombophilia (3,6).
APC resistance can be detected using an assay in which the clotting 
time of blood plasma is measured in the presence or absence of exo­
genous APC. When the ratio of the clotting times is below 0.84 X the
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normalised APC ratio, the patient is regarded as APC resistant. Be­
cause overlap in the APC ratios of patients and normal individuals can 
complicate diagnostics, an assay that allows direct detection of the fac­
tor V mutation can be of advantage. That way patients who are being 
treated with anticoagulants and for whom no proper APC ratio can be 
measured, can al so be screened for the G 1691A mutati on.
Current methods to determine the G 1691A mutation include DNA 
sequencing, polymerase chain reaction (PCR) and subsequent restric­
tion digestion with Mnl I or Southern blotting of the PCR products and 
subsequent probing with allele specific oligonucleotides (3). For rou­
tine screening of patient samples a simple, fast and cost-effective 
method is important. The method we describe here is based upon a 
single PCR followed by direct analysis by Capillary Electrophoresis 
(CE) and on line UV detection. The semi-automated protocol is ap­
plicable for the molecular diagnosis of other diseases that are based on 
the presence of a point mutation.
Materials and Methods
DNA Isolation and Amplification
Genomic DNA was isolated from whole EDTA blood by salt extraction (7) 
and 1 [ig was amplified by PCR in 50 (jl! containing 50 mM KC1,20 mM Tris 
pH 8.4, L5 mM MgCl2, 0.001% gelatine, 125 mM dNTPs, 15 pmol of each 
primer (see Table 1) and 2.5 U Taq polymerase (Gibco BRL, Gaithersburg, 
USA) and overlaid with 80 fil mineral oil.
PCR amplification was performed in an Eppendorf Mastercycler (Eppen- 
dorf, Hamburg, Germany) starting with a denaturation step at 95°C for 5 min, 
followed by 35 or 40 cycles of 95° C for 30 s, 60 or 55° C for 30 s, 72° C for 
1 min 30 s. The number of cycles and the annealing temperature depends on the 
primer set used: the first set shown in Table 1A uses 35 cycles and 60° C and the 
second set in Table IB uses 40 cycles and 55° C. After the last cycle, the 
extension phase was prolonged to 10 min to allow full extension of all prod­
ucts. A sample of 15 (JlI was loaded on a 2 % agarose gel stained with 
ethidium bromide, the remainder was used for analysis with capillary 
electrophoresis.
Capillary Electrophoresis
Instrumentation: An uncoated fused silica capillary, 200 mm effective 
length and 0.075 mm internal diameter (SGE, Ringwood, Vic, Australia) was 
mounted in a User Assembled Cartridge and placed in a Biofocus 3000 CE 
instrument (Bio-Rad, Hercules, USA).
CE analysis: Prior to all analyses the capillary was purged, using a pressure 
of 100 psi, with water (15 s), 1 N NaOH (10 s), 0.1 N HC1 (10 s), 1XTBE 
(89 mM Tris-Borate, 0.2 mM EDTA, pH 8.3) (10 s), and then filled with Non 
Gel Sieving Buffer ( kindly provided by Bio-Rad, Hercules, USA) for 
90 s. This was followed by injection with 0.01 N acetic acid for 4 s for stacking 
purposes.
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Samples were pressure injected (400 psi * s) without pretreatment and se­
parated at reversed polarity (cathode at injection side) at 12.5 kV in NGSB as 
running buffer. The temperature of the cartridge and of the sample tray was 
20°C and 15°C respectively. On line UV absorption at 260 nm was used for 
detection.
Results and Discussion
Table 1 A) Sequence and position of primers used. First set of primers used in 
the PCR
prim er sequence position nr
ASO-1F 5-TTCAGCAGATCCCTGGACAGGCG-3' 1665-1691
ASO-1R 5'-AATAAGGACAAAATACCTGTATTCCTT-3' 1691-1717
CO-F 5'-CATACTACAGTGACGTGGACATCATG-3' 1576-1601
CO-R 5‘-TCTCTTGAAGGAAATGCCCCATTA-3’ intron 11
In order to generate PCR fragments that were derived from the nor­
mal or mutated allele, we used consensus oligonucleotides (COs, Table IB) Second set of primers
prim er sequence position nr
ASO-2F 5'-CATGCAGATCCCTGGACAGGTa-3’ 1669-1691
ASO-2R
i
5'- A AT G CGG AC A A A AT ACCTGT ATT CC C I-31 1691-1717
CO-2F 5-TACTACAGTGACGTGGACATCA-31 1578-1599
CO-2R S’-TCTCTTGAAGGAAATGCCCCAT-S1 intron 11
primers 1 and 4 in Fig. 1 A) as well as a set of specially designed allele- 
specific oligonucleotides (ASOs), The consensus oligonucleotides have 
a double function. Besides generating the allele specific products when 
used together with the allele-specific primers, the combination of both 
consensus primers generates a larger DNA fragment that serves as an 
internal control for quality and PCR efficacy of the patient sample. The 
allele-specific oligonucleotides have two important features. First, the 
sense or forward (F) primer (ASO-1F, primer 2 in Fig. 1A) has a 
guanine at the 3’ end, whereas the antisense or reverse (R) primer 
(ASCMR, primer 3 in Fig, 1 A) has a thymine at the 3s end. This way,
a
the primers were designed to be specific for the normal and mutant al­
lele respectively. As shown in Fig. IB, we expect the DNA from nor­
mal individuals to generate two products after PCR: a 202 bp internal
control fragment and a 138 bp product specific for the normal allele, with these primer sets is shown in Fig, IB. The results of agarose gel 
PCR on DNA from homozygous mutated individuals was expected to electrophoresis of PCR products using the ASO and CO primers in one
Allele-specific nucleotides are underlined, mismatches are depicted in bold, 
The position of the oligonucleotide primers is relative to the cDNA of factor V 
gene (8), the position and sequence of CO-R and CO-2R is derived from Zoller 
et al. (9)
generate a mutant-specific 115 bp DNA fragment next to the internal 
control fragment. PCR applied to DNA derived from an individual that 
is heterozygous for the G 1691A mutation was expected to result in the 
generation of all three fragments. As a second important feature, the 
allele-specific oligonucleotide primers have a stretch of mismatching 
bases at the 5’ end (indicated in Table 1). This is necessary to prevent 
the generation of heteroduplex DNA molecules of the internal standard 
molecule as a result of priming of the upper strand of the mutant-speci­
fic PCR product (upper fragment in Fig. 1C) with the lower strand of 
the normal PCR product (lower fragment in Fig. 1C) and subsequent 
extension by polymerase. Heteroduplex molecules could negatively 
interfere with subsequent electrophoretic analysis.
We tested a first primer set consisting of ASO-1F, ASO-1R and 
CO-F, CO-R primers (Table 1A) in a PCR on DNA samples derived 
from a normal and heterozygous individual. The results after agarose 
gel electrophoresis are shown in Fig. 2A. The 115 bp mutant-specific 
PCR product is not visible when the four primers are used in equal con­
centrations (Fig. 2A lane 6 vs. lane 2), We therefore tested the influence 
of altering the ratio of primers CO-F and ASO-1R versus primers ASO- 
IF and CO-R (Fig. 2B). This way, the amplification of the normal DNA 
sample showed a decrease in the amount of 138 bp product at a ratio of 
2:1 and 3:1 (Fig. 2B lane 3 and 4) while the amplification of the mu­
tant DNA sample showed a 138 bp normal band at a ratio 1:1 and 2:1 
(Fig. 2B lane 8 and 9). We concluded that this primer set gave rise to 
non specific amplification products which could lead to false test 
results.
We therefore changed the design of the mutant and normal oli­
gonucleotide primers and included an extra mismatch at the 3’ end of 
the allele-specific primers. The new set uses ASO-2F and ASO-2R 
primers which contain an extra mismatch directly adjacent to the allele- 
specific nucleotide at the 3' position (see Table IB), To match the lower 
annealing temperatures of the newly developed allele specific primers, 
we also synthesised two new consensus primers (CO-2F and CO-2R) 
(Table IB). The expected fragment lengths after DNA amplification
reaction is shown in Fig. 2C, Although the separation of the 137 bp 
fragment and 113 bp fragment is hardly visible after agarose gel 
electrophoresis, the new set seems to work in a specific manner. The 
identity of bands was confirmed by measuring their size after restriction 
digestion by Mnl I (data not shown). Because of the far better resolu­
tion, we subsequently analysed the products derived from controls and 
patient samples by capillary electrophoresis and on line UV detection.
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Fig. I A) Schematic drawing of ASAP-PCR, 1 = consensus primer (sense, 
CO-F), 2 = primer specific for normal allele .(ASOF), 3 = antisense primer 
specific for mutant allele (ASO-R), 4 = consensus primer (antisense, CO-R).
B) Length of the different PCR products for set 1 and set 2 respectively.
C) Mismatches in both allele-specific oligonucleotides to prevent formation of 
heteroduplexes in the PCR
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Fig, 2A) Analysis of PCR products on ethidiumbromide stained 2% agarose gel; M: 100 bp molecular weight marker, lane 1 - 4 wild type DNA. Lane 1 : Set 
of all four primers. Lane 2: primers CO-F and ASO-1R for amplification of mutant fragment. Lane 3: primers CO-R and ASO-1F for amplification of normal 
fragment. Lane 4: primers CO-F and CO-R for amplification of the internal standard fragment, Lanes 5 to 8: the same for heterozygous DNA. Lane 9: negative 
con trol.
B) The effect of different ratios of primer set CO-F and ASO-1R versus ASO-1F and CO-R. M: molecular weight marker. Lanes 1-3 for wild type DNA: ratios 
1:1» 2:1 and 3:1 respectively. Lanes 4-6 for heterozygous DNA and lanes 7 to 9 for homozygous mutant DNA, Lane 10 negative control.
C) M: molecular weight marker. Lanes 1 to 3: Results of amplification with the new primer set (CO-2F, ASO-2R and ASO-2F and CO-2R). Lane 1: DNA derived 
from normal person. Lane 2: DNA derived from heterozygous person. Lane 3: DNA derived from homozygous mutant individual. Lane 4: negative control
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We then performed a double-blind screening of DNA derived from 
20 patients and healthy control persons using the ASO-2F and 2R and 
CO-2F and 2R primer sets in one reaction. All resulting products were 
analysed by capillary electrophoresis. The results were 100% concor­
dant with the results found with the Mnl I digestion protocol as de­
scribed before (3).
The analysis by capillary electrophoresis showed good reproducibil­
ity although we observed a slight shift in migration times of peaks on 
the electropherogram when a large series of analyses were performed 
(n = 28, sd = 6.9%). This is caused by evaporation of Non Gel Sieving 
Buffer. When we determined relative migration times using the ratio of 
the migration times of the large fragment and the beginning of the PCR 
background material on the electropherogram (indicated in Fig. 3 as t0), 
the standard deviation in the migration times was minimal (n = 28; 
sd = 1.1%). In our current protocol, one CE analysis including purge 
and refill of the capillary takes about 12 min. A large series of samples 
(up to 25 samples) is analysed over night.
These data show that ASAP can be used to screen for factor V point 
mutation (G1691A). A similar approach using an extra mismatch at 
base four from the 3’ end was described by Norby et al. (11) to screen 
a mitochondrial DNA mutation causing Leber's hereditary optic neuro­
pathy. If the sequence surrounding the site of the mutation allows the 
design of allele-specific primers without internal loops and without a 
strong homology to other DNA sequences, ASAP can be used to 
screen point mutations in other genes. ASAP is a simple and fast 
procedure and when used together with analysis by capillary electro­
phoresis it is highly suitable for routine analysis of point mutations. The 
use of capillary electrophoresis has additional advantages, i. e. it has 
No non-specific results could be observed. The different electrophoret- excellent resolution and is highly reproducible, the performance is
Time (min)
Fig. 3 Results of analysis by capillary electrophoresis. Electropherograms de­
rived from normal, heterozygous and homozygous mutant and negative control 
after PCR
ic patterns are shown in Fig, 3. The peak on the electropherogram 
derived from the mutant allele is at 8,4 min, the normal allele at 
8,5 and the internal standard at 8.8 min.
fully automated and the detection is non-radioactive. As part of good 
laboratory practice (GLP), the raw data derived from the assay can be 
stored, subsequent data acquisition and analysis is easy.
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A  manual for every physician who is faced with skin lesions in 
daily practice. The malignant melanoma is increasing in incidence 
worldwide like no other malignant tumor and continues to entail 
high mortality, Therefore, early recognition is of literally vital 
importance. The authors have compiled a color atlas encompassing 
the clinical symptoms, histopathology and differential diagnoses 
of all the special forms of malignant melanoma, benign nevi and 
other pigmented skin lesions. At the head of every chapter a dia­
gram is provided which represents an idealized cross-section 
through the skin showing the clinical and histopathological appear­
ance of the individual skin lesions. A special chapter is dedicated 
to dermatoscopy, Didactically clear photographs of clinical find­
ings and of histopathological specimens complete the visual mate­
rial.
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